Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $280.00

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its price target increased by JPMorgan Chase & Co. from $272.00 to $280.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a "neutral" rating on the biopharmaceutical company's stock. JPMorgan Chase & Co.'s target price suggests a potential upside of 18.76% from the company's current price.

ALNY has been the subject of several other reports. StockNews.com lowered Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, January 9th. Royal Bank of Canada reiterated an "outperform" rating and issued a $310.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. HC Wainwright increased their price target on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a "buy" rating in a report on Monday, February 24th. William Blair reaffirmed an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Finally, Wolfe Research downgraded Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a research note on Tuesday, November 12th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $304.26.

Remove Ads

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock traded up $2.70 during trading hours on Tuesday, hitting $235.77. 79,871 shares of the stock were exchanged, compared to its average volume of 788,652. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39. The business's 50-day moving average is $254.70 and its two-hundred day moving average is $261.25. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The stock has a market capitalization of $30.52 billion, a P/E ratio of -108.85 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). Equities research analysts expect that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the transaction, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Pushkal Garg sold 1,548 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the completion of the sale, the chief marketing officer now owns 11,989 shares of the company's stock, valued at approximately $3,017,271.63. This trade represents a 11.44 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 72,986 shares of company stock valued at $20,397,849. 1.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Farther Finance Advisors LLC grew its stake in shares of Alnylam Pharmaceuticals by 95.4% in the third quarter. Farther Finance Advisors LLC now owns 211 shares of the biopharmaceutical company's stock worth $58,000 after purchasing an additional 103 shares in the last quarter. QRG Capital Management Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $221,000. Assetmark Inc. boosted its position in shares of Alnylam Pharmaceuticals by 8.2% in the third quarter. Assetmark Inc. now owns 9,186 shares of the biopharmaceutical company's stock worth $2,526,000 after buying an additional 700 shares during the period. Atria Investments Inc boosted its position in Alnylam Pharmaceuticals by 78.9% during the 3rd quarter. Atria Investments Inc now owns 3,145 shares of the biopharmaceutical company's stock worth $865,000 after acquiring an additional 1,387 shares during the period. Finally, GSA Capital Partners LLP increased its stake in shares of Alnylam Pharmaceuticals by 55.3% in the third quarter. GSA Capital Partners LLP now owns 2,860 shares of the biopharmaceutical company's stock worth $787,000 after acquiring an additional 1,018 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.